Nina Cohen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nina Cohen has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Susan K. Seo
Memorial Sloan Kettering Cancer Center
2 shared publications - Addison K. May
Department of Surgery, Atrium Health Carolinas Medical Center
1 shared publication Carrie Tan
Department of Pharmacy , Memorial Sloan Kettering Cancer Center, New York, New York
1 shared publicationElizabeth V Robilotti
Infection Control , Memorial Sloan Kettering Cancer Center, New York, New York
1 shared publicationJerome Fender
Infection Control , Memorial Sloan Kettering Cancer Center, New York, New York
1 shared publicationJiselle M. Bock
Department of Surgery, Atrium Health - Cleveland, Shelby, NC http://www.twitter.com/jisellebockmd
1 shared publication
Latest Publications
- Open Access
- 29 November 2022
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 76 (8) , 1476-1482
Predictors of Coronavirus Disease 2019 Hospitalization After Sotrovimab in Patients With Hematologic Malignancy During the BA.1 Omicron Surge
Sotrovimab is an anti-spike neutralization monoclonal antibody developed to reduce the risk of coronavirus disease 2019 (COVID-19) progression and advancement to hospitalization in high-risk patients. Currently, there is limited research describing the association of sotrovimab treatment in patients with hematologic malignancy and the predictive factors of hospitalization. We performed an observational study of 156 consecutive cancer patients who received sotrovimab at Memorial Sloan Kettering Cancer Center in New York City during the BA.1 Omicron surge. We evaluated the demographic, clinical, and laboratory characteristics of the patients who had subsequent COVID-19–related hospitalization(s) compared to those who did not. Among the 156 study patients, 17 (11%) were hospitalized, of whom 4 were readmitted for COVID-19–related complications; 3 deaths were attributed to COVID-19. Results from multivariable logistic regression show that significant factors associated with hospitalization include patients on anti-CD20 therapy (adjusted odds ratio [aOR], 5.59 [95% confidence interval {CI}, 1.73–18.12]; P = .004) and with relapse/refractory disease (aOR, 5.69 [95% CI, 1.69–19.16]; P = .005). Additionally, whole genome sequencing of severe acute respiratory syndrome coronavirus 2 detected high occurrences of mutations in the spike gene associated with treatment-related resistance longitudinal samples from 11 patients treated with sotrovimab. While sotrovimab is effective at reducing COVID-19 hospitalization and disease severity in patients with hematologic malignancy when administered early, patients who received anti-CD20 antibodies showed substantial morbidity. Due to the high potential for resistance mutation to sotrovimab and increased morbidity in patients on anti-CD20 therapy, combination treatment should be explored to determine whether it provides added benefits compared to monotherapy.
- 29 November 2022
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 76 (8) , 1476-1482
Open AccessPredictors of Coronavirus Disease 2019 Hospitalization After Sotrovimab in Patients With Hematologic Malignancy During the BA.1 Omicron Surge
Sotrovimab is an anti-spike neutralization monoclonal antibody developed to reduce the risk of coronavirus disease 2019 (COVID-19) progression and advancement to hospitalization in high-risk patients. Currently, there is limited research describing the association of sotrovimab treatment in patients with hematologic malignancy and the predictive factors of hospitalization. We performed an observational study of 156 consecutive cancer patients who received sotrovimab at Memorial Sloan Kettering Cancer Center in New York City during the BA.1 Omicron surge. We evaluated the demographic, clinical, and laboratory characteristics of the patients who had subsequent COVID-19–related hospitalization(s) compared to those who did not. Among the 156 study patients, 17 (11%) were hospitalized, of whom 4 were readmitted for COVID-19–related complications; 3 deaths were attributed to COVID-19. Results from multivariable logistic regression show that significant factors associated with hospitalization include patients on anti-CD20 therapy (adjusted odds ratio [aOR], 5.59 [95% confidence interval {CI}, 1.73–18.12]; P = .004) and with relapse/refractory disease (aOR, 5.69 [95% CI, 1.69–19.16]; P = .005). Additionally, whole genome sequencing of severe acute respiratory syndrome coronavirus 2 detected high occurrences of mutations in the spike gene associated with treatment-related resistance longitudinal samples from 11 patients treated with sotrovimab. While sotrovimab is effective at reducing COVID-19 hospitalization and disease severity in patients with hematologic malignancy when administered early, patients who received anti-CD20 antibodies showed substantial morbidity. Due to the high potential for resistance mutation to sotrovimab and increased morbidity in patients on anti-CD20 therapy, combination treatment should be explored to determine whether it provides added benefits compared to monotherapy.
- Open Access
- 1 December 2014
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 1 (suppl_1) , S165
434Prevalence, Risk Factors, and Outcomes of Bacteremia Caused by Carbapenem-resistant Enterobacteriaceae in Neutropenic Patients with Hematologic Malignancies
Background. Neutropenic patients with hematologic malignancies rely on immediate, active antimicrobial therapy to combat bacterial infections, and thus are uniquely threatened by multidrug-resistant bacteria. Carbapenem-resistant Enterobacteriaceae (CRE) have emerged worldwide and are resistant to nearly all antimicrobial agents, but their impact on neutropenic patients is unknown.
- 1 December 2014
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 1 (suppl_1) , S165
Open Access434Prevalence, Risk Factors, and Outcomes of Bacteremia Caused by Carbapenem-resistant Enterobacteriaceae in Neutropenic Patients with Hematologic Malignancies
Background. Neutropenic patients with hematologic malignancies rely on immediate, active antimicrobial therapy to combat bacterial infections, and thus are uniquely threatened by multidrug-resistant bacteria. Carbapenem-resistant Enterobacteriaceae (CRE) have emerged worldwide and are resistant to nearly all antimicrobial agents, but their impact on neutropenic patients is unknown.